202 related articles for article (PubMed ID: 38288611)
21. Drug targeting systems for cancer therapy: nanotechnological approach.
Tigli Aydin RS
Mini Rev Med Chem; 2015; 14(13):1048-54. PubMed ID: 25138089
[TBL] [Abstract][Full Text] [Related]
22. Active targeting of gold nanoparticles as cancer therapeutics.
Goddard ZR; Marín MJ; Russell DA; Searcey M
Chem Soc Rev; 2020 Dec; 49(23):8774-8789. PubMed ID: 33089858
[TBL] [Abstract][Full Text] [Related]
23. Small molecules as cancer targeting ligands: Shifting the paradigm.
Kaur N; Popli P; Tiwary N; Swami R
J Control Release; 2023 Mar; 355():417-433. PubMed ID: 36754149
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in dual-ligand targeted nanocarriers for cancer therapy.
Khan N; Ruchika ; Dhritlahre RK; Saneja A
Drug Discov Today; 2022 Aug; 27(8):2288-2299. PubMed ID: 35439614
[TBL] [Abstract][Full Text] [Related]
25. Glyco-nanoparticles: New drug delivery systems in cancer therapy.
Khan H; Mirzaei HR; Amiri A; Kupeli Akkol E; Ashhad Halimi SM; Mirzaei H
Semin Cancer Biol; 2021 Feb; 69():24-42. PubMed ID: 31870939
[TBL] [Abstract][Full Text] [Related]
26. RNA Aptamer-functionalized Polymeric Nanoparticles in Targeted Delivery and Cancer Therapy: An up-to-date Review.
Marangoni K; Menezes R
Curr Pharm Des; 2022; 28(34):2785-2794. PubMed ID: 36056830
[TBL] [Abstract][Full Text] [Related]
27. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.
D'Souza AA; Devarajan PV
J Control Release; 2015 Apr; 203():126-39. PubMed ID: 25701309
[TBL] [Abstract][Full Text] [Related]
28. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
[TBL] [Abstract][Full Text] [Related]
29. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
[TBL] [Abstract][Full Text] [Related]
30. The ligand nanoparticle conjugation approach for targeted cancer therapy.
Karra N; Benita S
Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
[TBL] [Abstract][Full Text] [Related]
31. A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours.
Gupta N; Yadav V; Patel R
Curr Drug Deliv; 2022 Mar; 19(3):301-316. PubMed ID: 34391379
[TBL] [Abstract][Full Text] [Related]
32. Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors.
Ramzy L; Nasr M; Metwally AA; Awad GAS
Eur J Pharm Sci; 2017 Jun; 104():273-292. PubMed ID: 28412485
[TBL] [Abstract][Full Text] [Related]
33. Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting.
Ahmad A; Khan F; Mishra RK; Khan R
J Med Chem; 2019 Dec; 62(23):10475-10496. PubMed ID: 31339714
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of carbohydrate-based polymeric and nanoparticle systems.
Sunasee R; Adokoh CK; Darkwa J; Narain R
Expert Opin Drug Deliv; 2014 Jun; 11(6):867-84. PubMed ID: 24666000
[TBL] [Abstract][Full Text] [Related]
35. Carbohydrate-based magnetic nanocomposites for effective cancer treatment.
Shende P; Shah P
Int J Biol Macromol; 2021 Apr; 175():281-293. PubMed ID: 33571584
[TBL] [Abstract][Full Text] [Related]
36. Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review.
Tanbour R; Martins AM; Pitt WG; Husseini GA
Curr Pharm Des; 2016; 22(19):2796-807. PubMed ID: 26898742
[TBL] [Abstract][Full Text] [Related]
37. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
[TBL] [Abstract][Full Text] [Related]
38. Recent developments in carbohydrate-decorated targeted drug/gene delivery.
Zhang H; Ma Y; Sun XL
Med Res Rev; 2010 Mar; 30(2):270-89. PubMed ID: 19626595
[TBL] [Abstract][Full Text] [Related]
39. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.
Tian H; Zhang T; Qin S; Huang Z; Zhou L; Shi J; Nice EC; Xie N; Huang C; Shen Z
J Hematol Oncol; 2022 Sep; 15(1):132. PubMed ID: 36096856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
